NasdaqGS:ACADBiotechs
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Mixed Share Performance
Recent share performance and business context
ACADIA Pharmaceuticals (ACAD) has seen mixed share performance recently, with a 2.5% decline over the past day, a 3.6% gain over the past week, and weaker moves over the past month and past 3 months.
At a last close of US$21.47 and a market value of about US$3.8b, the company generates US$1,071.5m in revenue and US$391.0m in net income from its neurology focused medicines and pipeline programs.
See our latest analysis for ACADIA...